文献速递眼底病与葡萄膜炎神经眼科

表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌脉络膜转移的疗效:10年回顾

EFFICACY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR IN TREATING CHOROIDAL METASTASIS FROM NON-SMALL-CELL LUNG CANCER: A 10-Year Review.
PubMed 文献 · Retina · 2025-01-01

香港2家医院2013至2023年回顾性分析21例非小细胞肺癌脉络膜转移患者25只眼,发现酪氨酸激酶抑制剂单药、酪氨酸激酶抑制剂联合放疗及放疗和/或化疗组从1个月起肿瘤反应相似且眼部无进展指数可比,酪氨酸激酶抑制剂单药组视力增益最快且差异最大,作者认为酪氨酸激酶抑制剂可考虑作为传统眶部放疗或化疗的替代方案。

要点

  • 88%患眼诊断时有视觉症状,平均视力20/100,52%肿瘤位于黄斑区。
  • 酪氨酸激酶抑制剂单药、联合放疗及放疗和/或化疗组从1个月起肿瘤反应相似且眼部无进展指数可比。
  • 酪氨酸激酶抑制剂单药组视力增益最快且差异最大,未治疗患者视力恶化且无肿瘤反应。

核心结论

  • 酪氨酸激酶抑制剂在表皮生长因子受体突变阳性非小细胞肺癌脉络膜转移患者中实现持久疾病控制并改善视觉功能。
  • 鉴于视力恢复迅速,作者认为酪氨酸激酶抑制剂可考虑作为传统眶部放疗或化疗的替代方案。

研究设计与样本

  • 回顾性研究,纳入香港2家医院2013年至2023年收治的非小细胞肺癌脉络膜转移患者。
  • 共25只眼来自21例中国患者,评估治疗后肿瘤反应和视觉功能结局。

主要发现

  • 诊断时88%患眼有视觉症状,平均视力20/100,52%肿瘤位于黄斑区。
  • 酪氨酸激酶抑制剂单药组、酪氨酸激酶抑制剂联合放疗组及放疗和/或化疗组从1个月起肿瘤反应相似且眼部无进展指数可比。
  • 酪氨酸激酶抑制剂单药组视力增益最快且差异最大,未治疗患者视力恶化且无肿瘤反应。

临床怎么用

  • 作者认为酪氨酸激酶抑制剂可考虑作为表皮生长因子受体突变阳性非小细胞肺癌脉络膜转移患者传统眶部放疗或化疗的替代方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/PURPOSE: To describe the clinical characteristics of choroidal metastasis in patients with non-small-cell lung carcinoma and report treatment outcomes following targeted therapy versus conventional radiotherapy and/or chemotherapy. METHODS: A retrospective review was conducted in 2 hospitals in Hong Kong between 2013 and 2023. Outcomes included tumor response and visual function following treatment. RESULTS: A total of 25 eyes of 21 Chinese patients with choroidal metastasis secondary to metastatic non-small-cell lung carcinoma were identified. The majority of patients were nonsmokers. At the time of diagnosis, 88% of eyes were visually symptomatic with a mean visual acuity of 20/100. There were 52% of tumors locating within the macula. Tyrosine kinase inhibitor monotherapy, tyrosine kinase inhibitor with radiotherapy, and radiotherapy and/or chemotherapy groups were observed to demonstrate similar tumor response from 1 month and comparable ocular progression-free indices. Untreated patients had deteriorated vision without any tumor response. The tyrosine kinase inhibitor monotherapy group achieved the most rapid and differential vision gain than other groups. CONCLUSION: Tyrosine kinase inhibitor achieved durable disease control in epidermal growth factor receptor mutation-positive non-small-cell lung carcinoma patients with choroidal metastasis, while improving visual function. Tyrosine kinase inhibitor can be considered as an alternative to conventional orbital radiotherapy or chemotherapy for these patients in view of the rapid visual recovery.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Chee ASH, Mak ACY, Kam KW, et al. EFFICACY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR IN TREATING CHOROIDAL METASTASIS FROM NON-SMALL-CELL LUNG CANCER: A 10-Year Review. Retina. 2025. PMID: 39504451. doi:10.1097/IAE.0000000000004314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。